Close Menu
إستثمار
    الأكثر مشاهدة

    هيئة السياحة الماليزية تطلق كرنفال “زوروا ماليزيا 2026-2027” في جدة لتعزيز السياحة العائلية

    موضة وأزياء

    “ساديا حلال” تحصد جائزة نيلسن آي كيو للابتكار النوعي لعام 2026 في السعودية

    تجارة وأعمال

    “كيندريل” : قادة الأعمال بدولة الإمارات يدفعون عجلة اعتماد الذكاء الاصطناعي مع التركيز على الحوكمة

    تجارة وأعمال
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    إستثمار
    • الرئيسية
    • رئيسي
    • أخبار عامة
    • أسهم
    • English News
    • سياحة وسفر
    • سيارات
    • عقارات
    • مال و أعمال
    • مقالات
    إستثمار
    الرئيسية»English News»Novo’s Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

    Novo’s Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026

    Facebook Twitter LinkedIn WhatsApp Email
    مشاركة
    Facebook Twitter LinkedIn Email WhatsApp

    Statistically significant reductions in food noise scores from baseline were observed in adults taking semaglutide injection within the first month of initiation and through six months in the SIGNAL study1

                Oral semaglutide was associated with about a 25% reduction from baseline in reported average food noise scores over three months in the OCTANE study. Most adults (86.4%) reported at least one treatment improvement2

                Food noise is an emerging area of research in obesity care, with real-world studies suggesting semaglutide may provide an additional patient-centered benefit beyond weight loss

     

    Today, Novo Nordisk presented real-world findings from the SIGNAL and OCTANE studies at ObesityWeek® 2026, looking at how food noise scores changed for adults with overweight or obesity taking Wegovy® injection or Wegovy® pill.1,2 Both retrospective cohort analyses used de-identified patient data from the Ro telehealth platform and a validated seven-item questionnaire to assess food noise, defined as persistent, intrusive and unwanted thoughts about food.

     “Patients at our center often describe persistent and intrusive thoughts about food, and that managing those thoughts can take a toll on their day-to-day lives,” said Louis J. Aronne, MD, Director of the Comprehensive Weight Control Center, Weill Cornell Medicine, and co-author of the studies. “The SIGNAL and OCTANE findings showed that semaglutide injection and oral semaglutide were associated with early reductions in food noise in real-world studies. Looking forward, additional research can help clarify the clinical relevance of such food noise and its place in everyday obesity care”

    The two presented studies examined changes in patient-reported food noise scores over time among adults with overweight or obesity taking semaglutide in a real-world telehealth setting, using the validated seven-item Ro Allison Indiana Dhurandhar–Food Noise Inventory (RAID-FN) questionnaire, which measures persistent, intrusive and unwanted thoughts about food.1,2

    In the SIGNAL study, 26,213 treatment-naïve adults with obesity or overweight with at least one weight-related condition initiating semaglutide injection were followed for up to six months in a  real-world telehealth setting.1 The adjusted mean baseline RAID-FN total score was 2.72 (95% CI 2.71, 2.74).1 Mean food noise scores decreased within the first month, with an adjusted mean change from baseline of -0.42 points (95% CI -0.43, -0.41).1 The greatest reductions were observed during the first three months, and reductions were maintained through month 6, when the adjusted mean change from baseline was  -0.72 points (95% CI: -0.74 to -0.70

    In the OCTANE study, adults initiating oral semaglutide reported a statistically significant reduction in average food noise scores over 3 months, reducing by ~25% from baseline (total RAID-FN score 2.8 to 2.1 (p<0.001)).2 At program entry, participants’ most commonly reported treatment goals were to lose weight (98.0%), improve general physical health (76.5%), and increase confidence in their appearance (54.5%).¹ Participants also commonly reported weight-related impacts on confidence, clothing, sense of self and energy.2 At three months, 86.4% reported at least one treatment improvement, including better-fitting clothing (67.5%), healthier eating (51.6%), more physical activity (26.8%), more energy during the day (26.6%), improved mood (21.7%), fewer alcohol cravings (18.8%) and better sleep 18.6%

     “As GLP-1 medicines, like Wegovy®, become more widely used and discussed, many people have asked about their impact on food noise as they think about treatment,” said Michelle Skinner Moore, PharmD, MBA, interim head of clinical development, medical and regulatory affairs and vice president, medical affairs at Novo. “While food noise remains an emerging area of research, at Novo, we are working to advance the science of obesity and broaden understanding beyond changes on the scale. These real-world findings from the SIGNAL and OCTANE studies, conducted in partnership with Ro, contribute to our efforts to better understand the lived experiences of people with obesity and the outcomes they say matter to them”

    Real-world evidence can complement randomized controlled trials, which are the gold standard for evaluating a treatment’s safety and efficacy.4 Real-world studies evaluate associations and cannot determine causality.  Limitations of the SIGNAL and OCTANE studies include: variable timing and completeness of data being collected during routine telehealth care; potential bias associated with self-reported data; possible selection bias resulting from the treatmentpersistence requirement; and limited generalizability to the broader population

    It is important to note that semaglutide injection 2.4 mg and semaglutide tablets 25 mg contain a Boxed Warning for possible thyroid tumors, including cancer, and should not be used in those with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, changes in skin sensations, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and hair loss

    مشاركة. Facebook Twitter LinkedIn WhatsApp Email
    المقالة السابقة«ملاذ للتأمين» تطلق منتج تأمين «كامن» بتغطيات مبتكرة
    المقالة التالية كونغرس إسطنبول.. كريملوف المرشح الوحيد لرئاسة الاتحاد الدولي للملاكمة
    admin
    • الموقع الالكتروني

    إقرأ أيضا

    English News

    Barraquer Eye Hospital UAE Offers Complimentary Retinal Screenings to Mark World Diabetes Day

    English News
    English News

    06 Mall by Alef Group introduces Sharjah’s first and largest 3D advertising screen with CITIX MENA

    English News
    English News

    Novo’s CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026

    English News
    English News

    Samsung’s Latest Products Recognized by Consumer Technology Association Ahead of CES 2027

    English News
    اترك تعليقك إلغاء الرد

    مختارات
    إقرأ أيضا
    موضة وأزياء

    هيئة السياحة الماليزية تطلق كرنفال “زوروا ماليزيا 2026-2027” في جدة لتعزيز السياحة العائلية

     تستعد مدينة جدة لاستضافة فعاليات كرنفال “زوروا ماليزيا 2026-2027” الذي تنظمه هيئة السياحة الماليزية يومي…

    “ساديا حلال” تحصد جائزة نيلسن آي كيو للابتكار النوعي لعام 2026 في السعودية

    تجارة وأعمال

    “كيندريل” : قادة الأعمال بدولة الإمارات يدفعون عجلة اعتماد الذكاء الاصطناعي مع التركيز على الحوكمة

    تجارة وأعمال

    “شفرة” تؤسس مقرها الرئيسي في السعودية

    تكنولوجيا و اتصالات

    منصة إخبارية تلتزم بمعايير الدقة والحيادية والموضوعية من خلال تغطية دقيقة للأحداث،تهتم بمنطقة الشرق الأوسط خاصة دول الخليج العربي.

    راسلنا عبر البريد الالكتروني : info@blog.yoszero.online

    تصنيفات
    • English News
    • News English
    • أخبار عامة
    • أسهم
    • اخبار
    • اخبار عامه
    • اقتصاد
    • تجارة وأعمال
    • تجاره وأعمال
    • ترفيه وفعاليات
    • تقنية
    • تكنولوجيا و اتصالات
    • رئيسي
    • رياضة
    • رياضه
    • سياحة وسفر
    • سياحه وطيران
    • سيارات
    • صحة
    • صحة و جمال
    • صحة وجمال
    • صحه وجمال
    • عقارات
    • علوم وتكنولوجيا
    • فن ومنوعات
    • فيديو
    • مال و أعمال
    • مال وأعمال
    • مقالات
    • موضة وأزياء
    تابع أيضا

    جدة تستضيف المنتدى الخامس للأمراض المناعية

    صحة

    شركة هيونداي موتور تُعيّن طارق مسعد رئيسًا ومديرًا تنفيذيًا لمقرها الإقليمي في الشرق الأوسط وأفريقيا

    سيارات

    توقيع مذكرة تفاهم بين شركة نوفو نورديسك وجمعية القلب السعودية لتحسين صحة القلب والأوعية الدموية في السعودية

    صحة
    إستثمار
    Facebook X (Twitter) Instagram
    • الرئيسية
    • صحة
    • سيارات
    • رياضة
    2026 © كل الحقوق محفوظة

    اكتب كلمة البحث أو اضغط Esc لإلغاء شاشة البحث